A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder



Status:Completed
Conditions:Psychiatric, Bipolar Disorder
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 60
Updated:4/19/2017
Start Date:April 2003
End Date:February 2007

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

The purpose of this study is to determine if galantamine augmentaion improves cognition in
euthymic bipolar patients. In addition, the effect of galantamine on clinical measures of
functioning and psychopathology will also be assessed.

The study length is 12 to 24 weeks depending on whether patients enter the crossover. Study
also involves 3 neuropsychology testings.

Inclusion Criteria:

- Age 18-60; DSM-IV diagnosis of bipolar disorder, any subtype; Baseline Mini Mental
Status exam above 20; MRS < 16; MADRS < 16

Exclusion Criteria:

- Current substance dependence; serious unstable medical conditions; active suicidal
ideation; current DSM-IV for a major mood episodes; history of COPD, epilepsy,
cardiac arrhythmia, and peptic ulcer disease; meet DSM-IV criteria for dementia
We found this trial at
1
site
Cambridge Health Alliance
Cambridge, Massachusetts 02139
?
mi
from
Cambridge, MA
Click here to add this to my saved trials